Sökresultat

MultiPark’s scientists conduct world-leading research in biomarkers for Alzheimer’s disease, led by Professor Oskar Hansson at the memory clinic at Skåne University Hospital. He recently met with Bill Gates to discuss the future possibilities in this field. You met with Bill Gates yesterday in Brussels. Why did he want to meet you there? Already five years ago, Gill Gates understood the importance

https://www.multipark.lu.se/article/multipark-researcher-bill-gates-brussels - 2025-10-09

A large study led by Lund University in Sweden has shown that people with Alzheimer's disease can now be identified before they experience any symptoms. It is now also possible to predict who will deteriorate within the next few years. The study is published in Nature Medicine, and is very timely in light of the recent development of new drugs for Alzheimer's disease. It has long been known that t

https://www.multipark.lu.se/article/alzheimers-disease-can-be-diagnosed-symptoms-emerge - 2025-10-09

MultiPark’s backbone for research interactions is about to be reorganized. The 13 new special interest groups (SIGs) address essential scientific and technological needs and provide opportunities for professional development and network formation to our young scientists. The SIGs are self-organizing and self-managing groups. Brian Circuit Analysis is one of them with already ongoing activities. An

https://www.multipark.lu.se/article/brain-circuit-analysis-special-interest-group - 2025-10-09

The glymphatic system clears waste products from the brain. Roberta Battistella defends her thesis about the role of this system in Parkinson’s disease on December 1. Here, she tells about her time as a Ph.D student in Iben Lundgaards research group at MultiPark. Tell us about your research! “The glymphatic system removes waste products from the brain with the help of cerebrospinal fluid (CSF). It

https://www.multipark.lu.se/article/glymphatic-system-pd-phd-interview-roberta-battistella - 2025-10-09

The brain's big-eating immune cells can slow down the progression of Alzheimer's disease. This is shown by a study that is now published in Nature Aging. The brain's own immune cells are called microglia and are found in the central nervous system. They are big eaters that kill viruses, damaged cells and infectious agents they come across. It has long been known that microglial cells can be activa

https://www.multipark.lu.se/article/brains-immune-cells-can-be-triggered-slow-down-alzheimers-disease - 2025-10-09

Walking is probably more cognitively demanding than you think. Magnus Lindh-Rengifo defends his thesis about walking aspects in neurodegenerative disorders on December 16. Read about his experiences as a Ph.D student at MultiPark. Tell us about your research! “Walking capability can be a key feature to being able to participate in meaningful activities in your daily life. Meeting patients with neu

https://www.multipark.lu.se/article/walking-neurodegeneration-phd-interview-magnus-lindh-rengifo - 2025-10-09

A new study have identified which blood tests are best at detecting Alzheimer’s disease during the earliest stages, and also another blood test that is optimal for detecting relevant treatment effects. These findings will speed up the development of new therapies that can slow down the disease progression. The article was originally published as a press release from the Sahlgrenska Academy, Univer

https://www.multipark.lu.se/article/optimal-blood-tests-development-new-therapies-alzheimers-disease - 2025-10-09

“Lundensare” Nobel Prize winner Arvid Carlsson (1923-2018) did not receive the prestigious Nobel Prize while living or working in Lund – but he is an alumnus! Carlsson grew up in Lund (which could clearly be heard in his Lund accent) and in 1951 he became a doctor of medicine at Lund University. He was employed as an associate professor of pharmacology and in 1959 he left for Gothenburg, where he

https://www.multipark.lu.se/article/nobel-prize-winner-arvid-carlsson-7-things-you-perhaps-did-not-know-about-him-and-his-research - 2025-10-09

MultiPark’s new special interest groups (SIGs) address essential scientific and technological needs and provide opportunities for professional development and network formation to our young scientists. One of them focus on molecular signaling. Lautaro Belfiori is the convening person. He shares with us how they plan to work with questions related to molecular signaling. Can you shortly describe th

https://www.multipark.lu.se/article/molecular-signaling-neurodegenerative-disorders-special-interest-group - 2025-10-09

Keivan Javanshiri’s Ph.D. project explores cardiac and vascular pathologies in Lewy body dementia and Alzheimer's disease. January 20, he defends his thesis. Here, he shares the most important findings and why sudden cardiac arrest is a common cause of death in patients with Lewy body disease. Tell us about your research! “My research focuses on cognitive disorders, which you may envision like a t

https://www.multipark.lu.se/article/cognitive-disease-beyond-brain-phd-interview-keivan-javanshiri - 2025-10-09

We ended the MultiPark year in December as we started it in January: with a MultiPark Retreat! The December retreat was our first big meeting IRL after the pandemic, and it turned out to be a much appreciated event. Thank you to all participants, and thank you once again to the retreat organizing committee for doing such a great job! 2022 was a year of “reopening”. Like a butterfly spreads its win

https://www.multipark.lu.se/article/multipark-closing-circle-2022-and-looking-forward-2023 - 2025-10-09

Katrine Skovgård’s Ph.D. project sheds light on the dysfunctions in the brain through which dopaminergic pharmacotherapies for Parkinson’s disease affect motor behaviors. January 19, she defends her thesis. She explains how better experimental models might improve future translational research on dyskinesia. You presented your research at the MultiPark Café recently. But for those who could not at

https://www.multipark.lu.se/article/why-dopamine-receptor-type-matters-phd-interview-katrine-skovgard - 2025-10-09

At the end of October 2022, the Swedish Medical Products Agency gave the go-ahead for a clinical trial of the stem cell-based therapy STEM-PD for the treatment of Parkinson’s disease. The cells, generated from embryonic stem cells, have been in development for several years and will now be transplanted into patients with Parkinson’s to replace nerve cells lost due to the disease. The clinical tria

https://www.multipark.lu.se/article/nerve-cells-could-transform-treatment-parkinsons - 2025-10-09

Huntington's disease is known as the "dance disease" due to the patient's characteristic motor symptoms. However, Elna Dickson's Ph.D. project shows that the disease also leads to pathological changes outside the brain. February 17, she defends her thesis about metabolic alterations in Huntington's disease. Now, she shares perspectives on her research journey. Tell us about your research! "Hunting

https://www.multipark.lu.se/article/huntingtons-metabolic-dysfunctions-phd-interview-elna-dickson - 2025-10-09

The aggregation of the protein Amyloid-beta (Abeta) into plaques outside the nerve cells has been recognized in patients with Alzheimer’s disease since 1905. But eliminating the plaques has not helped patients so far. Still, Tomas Roos thinks that Abeta matters, but we may need to focus on the aggregates elsewhere. On February 17, he defends his thesis about prion-like proteins in neurodegeneratio

https://www.multipark.lu.se/article/does-alzheimers-disease-start-inside-neurons-phd-interview-tomas-roos - 2025-10-09

On 13th of February, a transplant of stem cell-derived nerve cells was administered to a person with Parkinson’s at Skåne University Hospital, Sweden. The product has been developed by Lund University and it is now being tested in patients for the first time. The transplantation product is generated from embryonic stem cells and functions to replace the dopamine nerve cells which are lost in the p

https://www.multipark.lu.se/article/first-patient-receives-milestone-stem-cell-based-transplant-parkinsons-disease - 2025-10-09

The boundaries between biology and technology are becoming blurred. Researchers at Linköping, Lund, and Gothenburg universities in Sweden have successfully grown electrodes in living tissue using the body’s molecules as triggers. The result, published in the journal Science, paves the way for the formation of fully integrated electronic circuits in living organisms. This news was initially publish

https://www.multipark.lu.se/article/electrodes-grown-brain - 2025-10-09

Kajsa Brolin explores how our genes and environment affect the risk of developing Parkinson’s disease. March 27, she defends her Ph.D. project partly based on MultiPark’s biobank sample collection. Here, she tells about the newly discovered genetic risk factor that might be specific to people in the southern part of Sweden. And is coffee really protective? Tell us about your research! “My research

https://www.multipark.lu.se/article/genes-and-environment-pd-phd-interview-kajsa-brolin - 2025-10-09

After a decade of protocol development and preparations, MultiPark researchers have finally launched the clinical trial. Recently, dopamine-producing cells generated from embryonic stem cells were transplanted into the first Parkinson's patient at Skåne University Hospital. During the autumn 2022, the Swedish MPA (Läkemedelsverket) approved the clinical STEM-PD study. Several of MultiParks PIs hav

https://www.multipark.lu.se/article/stem-pd-bench-bedside-story-multipark-researchers-0 - 2025-10-09

Looking for the next step in your career? In need of some scientific inspiration? Or are you just curious about what MultiPark´s senior researchers are doing and their professional journey? Listen to MultiPark’s new podcast series “Meet our scientists”! In a newly launched podcast, young MultiPark researchers interview our research group leaders about their academic journey and main scientific foc

https://www.multipark.lu.se/article/meet-our-scientists-new-podcast-young-multipark-researchers - 2025-10-09